Furthermore, the absence of FSGS development in the patient subsequently treated with IL-17 inhibitor secukinumab could imply that this side effect may be specific to guselkumab rather than the overall inhibition of the IL-23/IL-17 axis. Here, IL37 is linked to focal segmental glomerulosclerosis.